Cargando…
Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy
BACKGROUND: Early highly active antiretroviral therapy (HAART), started within the first months of age, has been proven to be the optimal strategy to prevent immunological and clinical deterioration in perinatally HIV-infected children. Nevertheless, data about long-term follow-up of early treated c...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753343/ https://www.ncbi.nlm.nih.gov/pubmed/19709432 http://dx.doi.org/10.1186/1471-2334-9-140 |
_version_ | 1782172338366709760 |
---|---|
author | Chiappini, Elena Galli, Luisa Tovo, Pier-Angelo Gabiano, Clara Lisi, Catiuscia Bernardi, Stefania Viganò, Alessandra Guarino, Alfredo Giaquinto, Carlo Esposito, Susanna Badolato, Raffaele Di Bari, Cesare Rosso, Raffaella Genovese, Orazio Masi, Massimo Mazza, Antonio de Martino, Maurizio |
author_facet | Chiappini, Elena Galli, Luisa Tovo, Pier-Angelo Gabiano, Clara Lisi, Catiuscia Bernardi, Stefania Viganò, Alessandra Guarino, Alfredo Giaquinto, Carlo Esposito, Susanna Badolato, Raffaele Di Bari, Cesare Rosso, Raffaella Genovese, Orazio Masi, Massimo Mazza, Antonio de Martino, Maurizio |
author_sort | Chiappini, Elena |
collection | PubMed |
description | BACKGROUND: Early highly active antiretroviral therapy (HAART), started within the first months of age, has been proven to be the optimal strategy to prevent immunological and clinical deterioration in perinatally HIV-infected children. Nevertheless, data about long-term follow-up of early treated children are lacking. METHODS: We report data from 40 perinatally HIV-infected-children receiving early HAART, with a median follow-up period of 5.96 years (interquartile range [IQR]:4.21–7.62). Children were enrolled at birth in the Italian Register for HIV Infection in Children. Comparison with 91 infected children born in the same period, followed-up from birth, and receiving deferred treatment was also provided. RESULTS: Nineteen children (47.5%) were still receiving their first HAART regimen at last follow-up. In the remaining children the first regimen was discontinued, after a median period of 3.77 years (IQR: 1.71–5.71) because of viral failure (8 cases), liver toxicity (1 case), structured therapy interruption (3 cases), or simplification/switch to a PI-sparing regimen (9 cases). Thirty-nine (97.5%) children showed CD4(+ )T-lymphocyte values>25%, and undetectable viral load was reached in 31 (77.5%) children at last visit. Early treated children displayed significantly lower viral load than not-early treated children, until 6 years of age, and higher median CD4(+ )T-lymphocyte percentages until 4 years of age. Twenty-seven (29.7%) not-early treated vs. 0/40 early treated children were in clinical category C at last follow-up (P < 0.0001). CONCLUSION: Our findings suggest that clinical, virologic and immunological advantages from early-HAART are long-lasting. Recommendations indicating the long-term management of early treated children are needed. |
format | Text |
id | pubmed-2753343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27533432009-09-29 Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy Chiappini, Elena Galli, Luisa Tovo, Pier-Angelo Gabiano, Clara Lisi, Catiuscia Bernardi, Stefania Viganò, Alessandra Guarino, Alfredo Giaquinto, Carlo Esposito, Susanna Badolato, Raffaele Di Bari, Cesare Rosso, Raffaella Genovese, Orazio Masi, Massimo Mazza, Antonio de Martino, Maurizio BMC Infect Dis Research Article BACKGROUND: Early highly active antiretroviral therapy (HAART), started within the first months of age, has been proven to be the optimal strategy to prevent immunological and clinical deterioration in perinatally HIV-infected children. Nevertheless, data about long-term follow-up of early treated children are lacking. METHODS: We report data from 40 perinatally HIV-infected-children receiving early HAART, with a median follow-up period of 5.96 years (interquartile range [IQR]:4.21–7.62). Children were enrolled at birth in the Italian Register for HIV Infection in Children. Comparison with 91 infected children born in the same period, followed-up from birth, and receiving deferred treatment was also provided. RESULTS: Nineteen children (47.5%) were still receiving their first HAART regimen at last follow-up. In the remaining children the first regimen was discontinued, after a median period of 3.77 years (IQR: 1.71–5.71) because of viral failure (8 cases), liver toxicity (1 case), structured therapy interruption (3 cases), or simplification/switch to a PI-sparing regimen (9 cases). Thirty-nine (97.5%) children showed CD4(+ )T-lymphocyte values>25%, and undetectable viral load was reached in 31 (77.5%) children at last visit. Early treated children displayed significantly lower viral load than not-early treated children, until 6 years of age, and higher median CD4(+ )T-lymphocyte percentages until 4 years of age. Twenty-seven (29.7%) not-early treated vs. 0/40 early treated children were in clinical category C at last follow-up (P < 0.0001). CONCLUSION: Our findings suggest that clinical, virologic and immunological advantages from early-HAART are long-lasting. Recommendations indicating the long-term management of early treated children are needed. BioMed Central 2009-08-26 /pmc/articles/PMC2753343/ /pubmed/19709432 http://dx.doi.org/10.1186/1471-2334-9-140 Text en Copyright ©2009 Chiappini et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chiappini, Elena Galli, Luisa Tovo, Pier-Angelo Gabiano, Clara Lisi, Catiuscia Bernardi, Stefania Viganò, Alessandra Guarino, Alfredo Giaquinto, Carlo Esposito, Susanna Badolato, Raffaele Di Bari, Cesare Rosso, Raffaella Genovese, Orazio Masi, Massimo Mazza, Antonio de Martino, Maurizio Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy |
title | Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy |
title_full | Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy |
title_fullStr | Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy |
title_full_unstemmed | Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy |
title_short | Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy |
title_sort | five-year follow-up of children with perinatal hiv-1 infection receiving early highly active antiretroviral therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753343/ https://www.ncbi.nlm.nih.gov/pubmed/19709432 http://dx.doi.org/10.1186/1471-2334-9-140 |
work_keys_str_mv | AT chiappinielena fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT galliluisa fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT tovopierangelo fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT gabianoclara fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT lisicatiuscia fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT bernardistefania fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT viganoalessandra fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT guarinoalfredo fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT giaquintocarlo fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT espositosusanna fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT badolatoraffaele fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT dibaricesare fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT rossoraffaella fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT genoveseorazio fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT masimassimo fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT mazzaantonio fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy AT demartinomaurizio fiveyearfollowupofchildrenwithperinatalhiv1infectionreceivingearlyhighlyactiveantiretroviraltherapy |